LeMaitre Vascular reported third quarter 2026 revenue of $68.0 million, representing 11% year-over-year growth and slightly exceeding analyst estimates. While top-line performance was robust, GAAP diluted EPS of $0.65 fell below the $0.69 consensus, impacted by a 21% increase in operating expenses following a period of prior-year belt-tightening.
Key Highlights
- Organic sales growth reached 12%, comprised of a 7% increase in pricing power and a 5% improvement in unit volume.
- Gross margin remained strong at 71.7%, which reflected a 90 basis point adjusted expansion driven by higher average selling prices and operational efficiencies.
- Product performance was led by the vascular grafts segment, which grew 20%, and the international expansion of Artegraft, which saw sales increase 18%.
- Regional performance showed significant strength in the EMEA market with 18% growth, while the Americas and APAC regions grew 9% and 5% respectively.
- The company completed a $19.2 million acquisition of B. Braun vascular assets in October, adding a portfolio that generated $9.4 million in 2025 sales.